Jasper Therapeutics, Inc. financial data

Symbol
JSPR, JSPRW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2200 Bridge Pkwy Suite #102, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Amplitude Healthcare Acquisition Corp (to 9/29/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 978 % -11.2%
Debt-to-equity 15.3 % -5.15%
Return On Equity -64.7 % +6.92%
Return On Assets -56.1 % +6.25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares
Common Stock, Shares, Outstanding 15.1M shares -86.4%
Entity Public Float 111M USD +127%
Common Stock, Value, Issued 2K USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 15M shares +37.2%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +37.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 50.3M USD +21.4%
General and Administrative Expense 17.9M USD +6.25%
Operating Income (Loss) -68.2M USD -17%
Nonoperating Income (Expense) 1.41M USD -19.3%
Net Income (Loss) Attributable to Parent -62.4M USD -12.7%
Earnings Per Share, Basic -5.09 USD/shares +61.1%
Earnings Per Share, Diluted -5.09 USD/shares +61.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 107M USD -7.77%
Marketable Securities, Current 3.4M USD
Other Assets, Current 475K USD -27.3%
Assets, Current 109M USD -8.34%
Property, Plant and Equipment, Net 2.44M USD -20.2%
Operating Lease, Right-of-Use Asset 1.23M USD -26.9%
Other Assets, Noncurrent 1.16M USD +161%
Assets 114M USD -8.25%
Accounts Payable, Current 2.96M USD +87.5%
Employee-related Liabilities, Current 1.61M USD +73.5%
Liabilities, Current 10.1M USD +12.2%
Operating Lease, Liability, Noncurrent 1.29M USD -44.5%
Other Liabilities, Noncurrent 2.26M USD -2.16%
Liabilities 13.6M USD -2.48%
Retained Earnings (Accumulated Deficit) -198M USD -46.1%
Stockholders' Equity Attributable to Parent 100M USD -8.98%
Liabilities and Equity 114M USD -8.25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.7M USD -52.3%
Net Cash Provided by (Used in) Financing Activities 47.3M USD -53.4%
Net Cash Provided by (Used in) Investing Activities -25K USD +3.85%
Common Stock, Shares Authorized 492M shares 0%
Common Stock, Shares, Issued 15.1M shares -86.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 107M USD -7.74%
Deferred Tax Assets, Valuation Allowance 16.2M USD +60.4%
Deferred Tax Assets, Gross 47M USD +36.1%
Operating Lease, Liability 2.32M USD
Lessee, Operating Lease, Liability, to be Paid 2.51M USD
Property, Plant and Equipment, Gross 5.49M USD +10.7%
Operating Lease, Liability, Current 1.03M USD +12.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 740K USD -35.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.19M USD +110%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 194K USD -94.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 740K USD -37.7%
Deferred Tax Assets, Operating Loss Carryforwards 25.1M USD +21.7%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.42M USD +40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 740K USD
Operating Lease, Payments 285K USD +3.26%
Additional Paid in Capital 298M USD +21.4%
Depreciation, Depletion and Amortization 300K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 488K USD -13.3%
Share-based Payment Arrangement, Expense 1.48M USD +6.54%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%